Lupin today said it has received US health regulator's final approval to market Blisovi oral contraceptive tablets in different strengths in the American market.
"The company has received final approvals from the United States Food and Drug Administration (USFDA) to market generic versions of Warner Chilcott's Loestrin Fe 1/20 tablets and Loestrin Fe 1.5/30 tablets", Lupin said in a statement.
Lupin's US subsidiary, Lupin Pharmaceuticals Inc shall commence promoting the product in the US shortly, it added.
The tablets are indicated for prevention of pregnancy in women who chose to use oral contraceptives.
According to IMS MAT data, Loestrin Fe 1/20 had US sales of USD 139.7 million while Loestrin Fe 1.5/30 had sales of USD 55.5 million.
Shares of Lupin today closed 1.12 per cent up at Rs 1,860.35 apiece on the BSE.
